Status:
COMPLETED
Evaluating a Telemedicine Neurological Consult Program for Drug-Induced Movement Disorders Using the RE-AIM Framework
Lead Sponsor:
University of Vermont
Collaborating Sponsors:
Neurocrine Biosciences
Conditions:
Drug-Induced Movement Disorder
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
In this pilot study, the investigators will evaluate care delivery via telemedicine to individuals with drug-induced movement disorders (DIMDs). DIMDs can be disabling, and prevention is important; bu...
Eligibility Criteria
Inclusion
- 18 years or older
- Willing and able to provide consent
- Willing to have their Mental Health Clinician (MHC) share sensitive clinical information with the Neurology team
- Able to travel to Neurology clinic
- Have connectivity to Zoom using wi-fi or cellular data, either at home or a comfortable and private setting (such as MHC office)
Exclusion
- Currently hospitalized
- Neurologist determines patient requires care outside of the scope of the study
Key Trial Info
Start Date :
April 26 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 31 2024
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT06060444
Start Date
April 26 2022
End Date
October 31 2024
Last Update
November 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Vermont Medical Center
Burlington, Vermont, United States, 05401